Ichnos Glenmark Innovation (IGI) has introduced ISB 2301, a first-in-class multispecific immune cell activator designed for treating solid tumors. By targeting three tumor-associated antigens and engaging both T cells and NK cells, the candidate aims to overcome the limitations of conventional immunotherapies. IGI plans to file an Investigational New Drug (IND) application by the end of 2026 and anticipates initiating clinical trials in 2027, leveraging its proprietary BEAT® platform.
Advancing Oncology Treatment
Ichnos Glenmark Innovation (IGI), a global clinical-stage biotechnology firm, has officially announced ISB 2301 as its latest development candidate. As a multispecific immune cell activator, this novel molecule is engineered to trigger tumor cell death by simultaneously engaging T cells and natural killer (NK) cells. The candidate is specifically intended for the treatment of multiple solid tumor indications, addressing biological complexities that traditional immunotherapies have struggled to navigate.
Strategic Rationale and Technology
The development of ISB 2301 was made possible by IGI’s proprietary BEAT® technology platform. The molecule is designed to induce potent antibody-dependent cellular cytotoxicity (ADCC), effective checkpoint inhibition, and a sustained type 1 immune response. According to Dr. Lida Pacaud, President and CEO of IGI, the candidate represents a new benchmark for multispecific antibodies, matching the biological complexity of solid tumors with high mechanistic precision.
Future Development Roadmap
Having demonstrated excellent pharmacokinetics, tolerability, and a favorable safety profile in non-human primates, the company is moving forward with its regulatory and clinical timeline. IGI intends to submit an IND application for ISB 2301 by the end of 2026. Provided the regulatory process proceeds as planned, the company aims to begin clinical studies in 2027. This milestone follows the success of IGI’s prior lead investigational asset, ISB 2001, which previously secured a strategic collaboration with AbbVie.
Source: BSE
